CTRI/2018/04/013541
Not yet recruiting
Phase 2
Evaluation of safety and therapeutic efficacy of VAYU KEELAGA ILAKAM (Internal medicine) with ERUKKATHY THYLAM (External medicine) in the treatment of UTHIRA VATHA SURONITHAM(Rheumatoid arthritis). - Uthira Vatha Suronitham (Rheumatoid arthritis)
Ayothidoss Pandithar Hospital0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- UTHIRA VATHA SURONITHAM (Rheumatoid arthritis)
- Sponsor
- Ayothidoss Pandithar Hospital
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Insidious onset of polyarthritis with pain in the joints,Prolonged morning stiffness ( for 6 weeks or longer),Swelling of multiple involved joints (for 6 weeks or longer),Slow progressive signs of inflammation ,e.g.pain,Tenderness,warmth,eythymatous \> 6 weeks,Symmetrical joints involvement,Swelling especially in inter phalangeal joints,RA factor positive or Negative,Patients willing to admission in IPD or willing to attend OPD,Patients willing to undergo Radiological investigations and other laboratory investigations,Patient willing to sign the informed consent stating that she/he will consciously stick to the treatment during 48 days but can opt out the trial his/her own conscious discretion.
Exclusion Criteria
- •Pregnancy and lactation,Tubercular arthritis,Any other serious systemic illness like Cancer,Cardiac Diseases,osteoarthritis,Psoriatic arthritis,Gouty arthritis,Diabetic Mellitus,Hypertension,Characteristic deformities of hands ans feet in Rheumatoid arthritis,Systemic complication of Rheumatoid arthritis.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard antiretroviral therapy (ART) in the course of HIV-1 infection. A European multicenter, randomized, double-blind, placebo-controlled, phase II studyChronically infected HIV-1 patients under viral control on Anti-Retroviral therapyMedDRA version: 18.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Immune System Diseases [C20]EUCTR2013-002735-23-FRInnaVirVax90
Active, not recruiting
Phase 1
Assessment of the therapeutic properties of the VAC-3S immunoprotective vaccine when combined with standard therapy in the course of HIV infection.EUCTR2013-002735-23-ESInnaVirVax90
Active, not recruiting
Phase 1
Assessment of the therapeutic properties of a vaccine (VAC-3S) with regard to the protection of the immune system when combined with the standard of care antiretroviral therapy in the course of HIV-1 infection.EUCTR2013-002735-23-DEInnaVirVax SA90
Recruiting
Phase 2
A clinical study of Vranari Guggulu and Vrana lepa in the management of Diabetic Foot UlcerHealth Condition 1: null- Diabetic Foot UlcerCTRI/2015/02/005586DrNRS GovtAyurvedic College100
Recruiting
Phase 4
Effect of herbal medicine Vranari Guggulu and Vrana lepa for Diabetic Foot woundCTRI/2015/02/005587Dr Chadalawada Venkata Siva Koteswara Rao100